Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 30;206(11):451.
doi: 10.1007/s00203-024-04152-8.

The clinical praxis of bacteriocins as natural anti-microbial therapeutics

Safura Nisar  1 , Abdul Haseeb Shah  2 , Ruqeya Nazir  3
Affiliations
Review

The clinical praxis of bacteriocins as natural anti-microbial therapeutics

Safura Nisar et al. Arch Microbiol. .

Abstract

In recent decades, the excessive use of antibiotics has resulted in a rise in antimicrobial drug resistance (ADR). Annually, a significant number of human lives are lost due to resistant infectious diseases, leading to around 700,000 deaths, and it is estimated that by 2050, there could be up to 10 million casualties. Apart from their possible application as preservatives in the food sector, bacteriocins are gaining acknowledgment as potential clinical treatments. Not only this, these antimicrobial peptides have revealed in modulating the host immune system producing anti-inflammatory and anti-modulatory responses. At the same time, due to the ever-increasing global threat of antibiotic resistance, bacteriocins have gained attraction among researchers due to their potential clinical applications. Bacteriocins as antimicrobial peptides, represent one of the most important natural defense mechanisms among bacterial species, particularly lactic acid bacteria (LAB), that can fight against infection-causing pathogens. In this review, we are highlighting the potential of bacteriocins as novel therapeutics for inhibiting a wide range of clinically relevant and multi-drug-resistant pathogens (MDR). We also highlight the effectiveness and potential applications of current bacteriocin treatments in combating antimicrobial resistance (AMR), thereby promoting human health.

Keywords: Antibiotics; Antimicrobial resistance (AMR); Bacteriocins; Lactic acid bacteria; Novel therapeutics; Pathogens.

PubMed Disclaimer

References

    1. Abdul Hakim BN et al (2023) A comprehensive review of bioactive compounds from lactic acid bacteria: potential functions as functional food in dietetics and the food industry. Foods 12(15):2850 - PubMed - PMC - DOI
    1. Aljeldah MM (2022) Antimicrobial resistance and its spread is a global threat. Antibiotics 11(8):1082 - PubMed - PMC - DOI
    1. Al-Omari AW, Matter IR, Almola AH (2022) An overview of bacteriocin. Samarra J Pure Appl Sci 4(2):58–72
    1. Almeida-Santos AC et al (2021) Enterococcus spp. as a producer and target of bacteriocins: a double-edged sword in the antimicrobial resistance crisis context. Antibiotics 10(10):1215 - PubMed - PMC - DOI
    1. Amado CM et al (2020) Bacteriocin enterocin CRL35 is a modular peptide that induces non-bilayer states in bacterial model membranes. Biochim Biophys Acta (BBA) Biomembr 1862(2):183135 - DOI

MeSH terms

LinkOut - more resources